• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

GRAS Notices

  • Print
  • Share
  • E-mail
-

The inventory of GRAS notices provides information about GRAS notices filed since 1998, when FDA received its first GRAS notice. As of October 17, 2016, the GRAS final rule (81 FR 54960; August 17, 2016) requires a specific format for a GRAS notice. Prior to that date, FDA processed GRAS notices under the framework of the GRAS proposed rule (62 FR 18938; April 17, 1997). Notices received prior to the effective date of the GRAS final rule provide examples for potential notifiers for the types of information that may support a GRAS conclusion. In the inventory, notices follow the requirements for the format and content of a GRAS notice as of the effective date of the GRAS final rule.

We will update this information approximately monthly. More information about this inventory is available on the GRAS Notice Inventory Introduction page.


Search and display hints:

  • Select the specific GRN number below to view additional details about any GRAS Notice.
  • To sort by a specific field, click on the column header for that field.
  • To browse the records, use the Show All, First/Previous/Next/Last, and Jump To options at the bottom of the data table.
  • To search for a specific substance/term, enter the term in the Search box and select Show Items to display only those records that contain the selected term. (The search results also includes terms not shown on this page, but included in the full record on the detail page.)
  • The search results will return hits of records containing words that include the search term. For example, a search for the color red will return results that include terms such as reduce, ingredient, and cultured. To limit results to only the searched term, place a space before and after the word in the basic search or in the advanced search “this exact phrase” field.
Search within these results
Records Found: 793 Show All Page 1 of 16
GRN No.
(sorted Z-A)
Substance Date of closure FDA's Letter
793 Cultured corn starch fermented by Corynebacterium stationis Pending
792 Cultured corn starch fermented by Corynebacterium glutamicum Pending
791 Urolithin A Pending
790 Steviol glycosides (minimum purity 95%) Pending
789 Erythritol Pending
788 Pea protein Pending
787 Quinoa sprout powder Pending
786 Calcium propionate Pending
785 Calcium chloride Pending
784 Siraitia grosvenorii Swingle (Luo Han Guo) fruit extract Pending
783 Triacylglycerol lipase from Rhizopus oryzae produced in Aspergillus niger Pending
782 L-arabinose Pending
781 Alpha-tocopherol (fruit and vegetable derived) Pending
780 Rebaudioside M Pending
779 Isomalto-oligosaccharides Pending
778 Hemp seed oil Pending
777 Algal oil (55% docosahexaenoic acid) from Schizochytrium sp. FCC-3204 Pending
776 Algal oil (35% docosahexaenoic acid) from Schizochytrium sp. FCC-1324 Pending
775 Colicin Pending
774 Glutaminase from Bacillus licheniformis produced in Bacillus licheniformis Pending
773 Dried biomass of Chlamydomonas reinhardtii Pending
772 Green tea extract Pending
771 Hemp seed protein Pending
770 Potassium polyaspartate Pending
769 Vitamin C (fruit and vegetable derived) Pending
768 Stevia leaf extract Pending
767 Polyvinyl alcohol Pending
766 3'-sialyllactose sodium salt Pending
765 Hulled hemp seed Pending
764 Rebaudioside D Pending
763 Alpha-lactalbumin Pending
762 Carnobacterium divergens M35 preparation Pending
761 Esterified propoxylated glycerol May 25, 2018 FDA has no questions (in PDF) (105 kB)
760 Lactobacillus curvatus DSM 18775 Pending
759 Steviol glycosides consisting primarily of rebaudioside M produced in Yarrowia lipolytica May 25, 2018 FDA has no questions (in PDF) (106 kB)
758 Lactobacillus helveticus R0052, Bifidobacterium longum ssp. infantis R0033, and Bifidobacterium bifidum R0071 Pending
757 Preparation containing two bacterial phages specific to Escherichia coli O157 Pending
756 Endo-1,4-beta-glucanase from Trichoderma reesei Pending
755 D-psicose May 10, 2018 At the notifier's request, FDA ceased to evaluate this notice (in PDF) (56 kB)
754 Algal oil (87% oleic acid) derived from Prototheca moriformis strain S6697 Pending
753 Sodium thiocyanate Pending
752 Preparation containing the bacterial monophages, BP-63 and LVR16-A, specific to Salmonella Pending
751 Maltogenic alpha-amylase from Bacillus stearothermophilus produced in Bacillus subtilis Pending
750 Beta-glucosidase from Aspergillus niger Pending
749 2’-O-fucosyllactose Apr 23, 2018 FDA has no questions (in PDF) (95 kB)
748 Tomato powder Apr 19, 2018 At the notifier's request, FDA ceased to evaluate this notice (in PDF) (44 kB)
747 Calcium lactate Jun 1, 2018 FDA has no questions (in PDF) (76 kB)
746 Maltogenic amylase from Geobacillus stearothermophilus produced in Bacillus subtilis Pending
745 Steviol glycosides consisting primarily of rebaudioside M Apr 20, 2018 FDA has no questions (in PDF) (103 kB)
744 Steviol glycosides consisting primarily of rebaudioside M Mar 23, 2018 FDA has no questions (in PDF) (131 kB)

Show All 

jump to page of 16 


GRN No.
(sorted Z-A)
Substance Date of closure FDA's Letter

679661  

-
-